Walker, Patricia A
2 papers on CoChatORCID 0000-0002-2094-5138
Most cited papers
- Verified
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology
Multiple Myeloma Research and TreatmentsBone health and treatments
Cited by 48
- Verified
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 41
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free